The estimated Net Worth of Kathryn E Stein is at least 346 千$ dollars as of 7 January 2016. Kathryn Stein owns over 52,350 units of Macrogenics Inc stock worth over 345,909$ and over the last 11 years Kathryn sold MGNX stock worth over 0$.
Sign up
Kathryn Stein MGNX stock SEC Form 4 insiders trading
Kathryn has made over 6 trades of the Macrogenics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Kathryn exercised 52,350 units of MGNX stock worth 45,021$ on 7 January 2016.
The largest trade Kathryn's ever made was exercising 52,350 units of Macrogenics Inc stock on 7 January 2016 worth over 45,021$. On average, Kathryn trades about 15,179 units every 74 days since 2013. As of 7 January 2016 Kathryn still owns at least 95,555 units of Macrogenics Inc stock.
You can see the complete history of Kathryn Stein stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Kathryn Stein's mailing address?
Kathryn's mailing address filed with the SEC is C/O MACROGENICS, INC., 9640 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850.
Insiders trading at Macrogenics Inc
Over the last 11 years, insiders at Macrogenics Inc have traded over 27,036,278$ worth of Macrogenics Inc stock and bought 4,026,274 units worth 39,875,062$ . The most active insiders traders include Group Holdings (Sbs) Adviso...、Target N Vbb Biotech Ag Bio...、Edward Hurwitz. On average, Macrogenics Inc executives and independent directors trade stock every 21 days with the average trade being worth of 132,068$. The most recent stock trade was executed by Jay Philip Siegel on 20 May 2024, trading 4,500 units of MGNX stock currently worth 16,290$.
What does Macrogenics Inc do?
a career at macrogenics could be waiting for you! please click on "careers" ---------------------------->>> to learn more. macrogenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. macrogenics creates both differentiated molecules that are directed to novel cancer targets, as well as “bio-betters,” which are drugs designed to improve upon marketed medicines. the combination of macrogenics’ technology platforms and antibody engineering expertise has allowed the company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. these are exciting times at macrogenics and we hope that you will take the opportunity to learn more about our organization, our pipeline and to view our job opportunities!
What does Macrogenics Inc's logo look like?
Complete history of Kathryn Stein stock trades at Macrogenics Inc
Macrogenics Inc executives and stock owners
Macrogenics Inc executives and other stock owners filed with the SEC include:
-
Dr. Scott Koenig M.D., Ph.D.,
CEO, Pres & Director -
Dr. Scott Koenig,
CEO, Pres & Director -
Dr. Ezio Bonvini,
Sr. VP of Research & Chief Scientific Officer -
James Karrels,
Sr. VP, CFO & Corp. Sec. -
Eric Blasius Risser,
Sr. VP of Bus. Devel. & Portfolio Management and Chief Bus. Officer -
Dr. Stephen L. Eck,
Sr. VP of Clinical Devel. & Chief Medical Officer -
Dr. Stephen L. Eck M.D., Ph.D.,
Sr. VP of Clinical Devel. & Chief Medical Officer -
Dr. Christopher Shayne James M.D.,
VP of Investor Relations & Corp. Communications -
Lynn Cilinski,
VP, Controller & Treasurer -
Dr. Thomas M. Spitznagel,
Sr. VP of BioPharmaceutical Devel. & Manufacturing -
Jeffrey Stuart Peters,
Sr. VP & Gen. Counsel -
Anna Krassowska Ph.D.,
VP of Investor Relations & Corp. Communications -
David C Stump,
Director -
Kenneth Galbraith,
Director -
Lynn Cilinski,
VP, Controller and Treasurer -
Atul Saran,
See remarks -
Scott Thomas Jackson,
Director -
Karen Jean Ferrante,
Director -
Edward Hurwitz,
Director -
Matthew K Fust,
Director -
Ezio Bonvini,
Sr VP, Research & CSO -
Paulo F Costa,
Director -
Scott Koenig,
President and CEO -
Jay Philip Siegel,
Director -
Jon Marc Wigginton,
Sr VP, Clinical Dev. & CMO -
Kathryn E Stein,
Senior VP, Prd Dev & Reg Aff -
Stanford John Stewart,
V P, Clinical Oncology -
Biopharma Partners Iii Lpal...,
-
Group Holdings (Sbs) Adviso...,
-
Eran Nadav,
Director -
Arnold L Oronsky,
Director -
James Karrels,
SVP, CFO and Secretary -
William K Heiden,
Director -
Stephen L. Eck,
Chief Medical Officer -
Federica F. O'brien,
Director -
Eric Blasius Risser,
Chief Operating Officer -
Jeffrey Stuart Peters,
Senior VP and General Counsel -
Thomas Spitznagel,
Sr VP, Technical Ops -
Target N Vbb Biotech Ag Bio...,
-
Margaret Liu,
Director -
Meenu Chhabra,
Director